NASDAQ · Biotechnology

NXTS (NXTS) Stock

$1.54 -0.65% NASDAQ: NXTS Healthcare

Valuation

MetricValue
Price$1.54
Market Cap$87156
P/E Ratio-0.22
P/B Ratio0.31
P/S Ratio-83.75
EPS (TTM)$-25.02
52-Week High$89.92
52-Week Low$1.54
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-119.61%
ROA-37.56%
ROCE-33.33%
Gross Margin2.67%
Operating Margin103.62%
Net Margin155.62%
Debt/Equity0.03
Current Ratio6.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-6.0M$-7.0M$-4.0M$-5.0M
Net Profit$-5.0M$-6.0M$-7.0M$-5.0M$-4.0M
EPS$-504.05$-401.97$-190.14$-31.09$-25.02
Op Margin-1036.8%-1449.4%-2771.5%-1928.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$8.0M$6.0M$7.0M$5.0M$20.0M
Total Liabilities$1.0M$1.0M$1.0M$1.0M$5.0M
Cash$7.0M$6.0M$4.0M$2.0M$4.0M
Borrowings$0$0$0$0$1.0M

Latest News

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative GlobeNewswire · Jul 7, 2026 Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS) InvestorsHub · Jun 29, 2026 Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment GlobeNewswire · Jun 29, 2026 Top Midday Decliners MT Newswires · Jun 23, 2026 Top Premarket Decliners MT Newswires · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-5.0M$-3.0M$-3.0M$-4.0M
Investing Cash Flow$0$0$-2.0M$-2.0M$-3.0M
Financing Cash Flow$0$0$3.0M$3.0M$4.0M
Net Cash Flow$7.0M$-1.0M$-1.0M$-2.0M$2.0M
Free Cash Flow$-4.0M$-5.0M$-3.0M$-3.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.33
FCF Yield-79.93%
Quick Ratio4.73
Interest Coverage—
Return 1Y-95.41%
Return 3Y-99.75%
Return 5Y-99.98%

Ownership

Insiders Held21.17%
Institutions Held1.11%
Institutions Float Held1.40%
Institutional HolderSharesReport Date
Geode Capital Management, LLC7,1202026-03-31
Xtx Topco Ltd3,1092026-03-31
Yorkville Advisors Global, LP2,3442026-03-31
UBS Group AG1,8722026-03-31
Vanguard Fiduciary Trust Co9982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About NXTS

NXTS is led by CEO David Palach, employs 5 people, headquartered in IL, publicly traded since 2026.

NXTS stock trades at $1.54 with a market capitalization of $87156. The stock is valued at a price-to-earnings (P/E) ratio of -0.22, price-to-book of 0.31, price-to-sales of -83.75. Over the past 52 weeks the stock has ranged between $1.54 and $89.92, and currently trades 98.3% below its 52-week high.

On profitability, NXTS generates a return on equity (ROE) of -119.61%, return on capital employed of -33.33%, an operating margin of 103.62%, a net profit margin of 155.62%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides